Artykuły w czasopismach na temat „Rx-To-OTC Switch”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Sprawdź 50 najlepszych artykułów w czasopismach naukowych na temat „Rx-To-OTC Switch”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Przeglądaj artykuły w czasopismach z różnych dziedzin i twórz odpowiednie bibliografie.
Rosenau, Pauline Vaillancourt. "Rx-to-OTC Switch Movement." Medical Care Review 51, no. 4 (1994): 429–66. http://dx.doi.org/10.1177/107755879405100403.
Pełny tekst źródłaBonner, Loren. "In Rx-to-OTC switch, FDA approves first OTC retinoid." Pharmacy Today 22, no. 9 (2016): 28. http://dx.doi.org/10.1016/j.ptdy.2016.08.017.
Pełny tekst źródłaWion, Ann H. "RX-TO-OTC Switch—The Process and Procedures." Drug Information Journal 19, no. 2 (1985): 119–26. http://dx.doi.org/10.1177/009286158501900207.
Pełny tekst źródłaHalperin, Jerome A. "Strategic Issues in the Rx-to-OTC Switch." Drug Information Journal 24, no. 1 (1990): 13–18. http://dx.doi.org/10.1177/009286159002400104.
Pełny tekst źródłaPeck, Jonathan C. "Future Health Care Trends Affecting Rx-to-OTC Switch." Drug Information Journal 24, no. 1 (1990): 49–56. http://dx.doi.org/10.1177/009286159002400110.
Pełny tekst źródłaMarwick, Charles. "From Rx to OTC: More Drugs Make the Switch." JAMA: The Journal of the American Medical Association 278, no. 2 (1997): 103. http://dx.doi.org/10.1001/jama.1997.03550020033015.
Pełny tekst źródłaMarwick, C. "From Rx to OTC: more drugs make the switch." JAMA: The Journal of the American Medical Association 278, no. 2 (1997): 103. http://dx.doi.org/10.1001/jama.278.2.103.
Pełny tekst źródła&NA;. "No adverse effect of Rx-to-OTC switch for H2RAs." Reactions Weekly &NA;, no. 1046 (2005): 5. http://dx.doi.org/10.2165/00128415-200510460-00016.
Pełny tekst źródłaOster, Gerry, Daniel M. Huse, Thomas E. Delea, Graham A. Colditz, and James M. Richter. "The Risks and Benefits of an Rx-to-OTC Switch." Medical Care 28, no. 9 (1990): 834–52. http://dx.doi.org/10.1097/00005650-199009000-00012.
Pełny tekst źródłaHewitt, Nancy M., Joan M. Lausier, and Sara Rosenbaum. "Labeling and Advertising of OTC Medicines Special Emphasis on RX-to-OTC Switch Products." Clinical Research and Regulatory Affairs 11, no. 3-4 (1994): 207–23. http://dx.doi.org/10.3109/10601339409035943.
Pełny tekst źródłaHalperin, Jerome A. "Introduction to Session IV: What Comes after Rx-to-OTC Switch?" Drug Information Journal 19, no. 2 (1985): 177–78. http://dx.doi.org/10.1177/009286158501900219.
Pełny tekst źródłaChan, Clarissa. "FDA approves Rx-to-OTC switch of head lice removal product." Pharmacy Today 27, no. 1 (2021): 18–19. http://dx.doi.org/10.1016/j.ptdy.2020.12.008.
Pełny tekst źródłaGumbie, M., B. Parkinson, and H. Cutler. "Is The Oral Contraceptive Pill Rx to Otc Switch Cost-Effective?" Value in Health 21 (September 2018): S59. http://dx.doi.org/10.1016/j.jval.2018.07.446.
Pełny tekst źródłaChan, Clarissa. "FDA approves Rx-to-OTC switch of head lice removal product." Pharmacy Today 27, no. 1 (2021): 18–19. http://dx.doi.org/10.1016/j.ptdy.2020.12.008.
Pełny tekst źródłaPalumbo, Francis B. "The Impact of the Rx to OTC Switch on Practicing Pharmacists." American Pharmacy 31, no. 4 (1991): 41–43. http://dx.doi.org/10.1016/s0160-3450(16)33704-7.
Pełny tekst źródłaBowden, Mark, and Shalom I. Benrimoj. "Pharmacists' Attitudes Toward the Switch from Rx to OTC: The Australian Situation." Journal of Pharmaceutical Marketing & Management 10, no. 1 (1995): 29–43. http://dx.doi.org/10.3109/j058v10n01_03.
Pełny tekst źródłaPellise, L., and M. Serra. "The Economic Impact of an Hypothetical Rx-To-otc Switch in Spain." Value in Health 18, no. 7 (2015): A341. http://dx.doi.org/10.1016/j.jval.2015.09.146.
Pełny tekst źródłaMilonas, C., A. Milonas, D. Kouvelas, G. Dokios, and N. Maniadakis. "PHP84 The Economic Health Value from Rx to OTC Switch in Greece." Value in Health 15, no. 7 (2012): A303. http://dx.doi.org/10.1016/j.jval.2012.08.626.
Pełny tekst źródłaMillier, Aurelie, Joshua Cohen, and Mondher Toumi. "Economic Impact of a triptan Rx-To-OTC Switch in Six EU Countries." PLoS ONE 8, no. 12 (2013): e84088. http://dx.doi.org/10.1371/journal.pone.0084088.
Pełny tekst źródłaDr., Shivalika* Rohit Dhiman Sachin. "The Silent Pillars of Self-Care: A Deep Dive into Over-the-Counter Drug." International Journal of Pharmaceutical Sciences 3, no. 5 (2025): 3066–88. https://doi.org/10.5281/zenodo.15458796.
Pełny tekst źródłaMadhavan, Suresh, and Stephen W. Schondelmeyer. "Attitudes of Pharmacists Toward Rx-to-OTC Switches and Their Effect on Pharmacists' Overall Judgment of Switch Appropriateness." Journal of Pharmaceutical Marketing & Management 4, no. 4 (1990): 3–25. http://dx.doi.org/10.3109/j058v04n04_02.
Pełny tekst źródłaMadhavan, Suresh. "Attitudes of Pharmacists Toward Rx-to-OTC Switches and Their Effect on Pharmacists' Overall Judgment of Switch Appropriateness." Journal of Pharmaceutical Marketing & Management 4, no. 4 (1990): 3–25. http://dx.doi.org/10.1300/j058v04n04_02.
Pełny tekst źródłaSchneider-Ziebe, Anissa, and Uwe May. "The treatment of migraine patients with triptans – is there a need for further Rx-to-OTC switches?" Gesundheitsökonomie & Qualitätsmanagement 25, no. 01 (2019): 15–23. http://dx.doi.org/10.1055/a-0836-2852.
Pełny tekst źródłaWei, Jianxiang, Guanzhong Feng, Zhiqiang Lu, Pu Han, Yunxia Zhu, and Weidong Huang. "Evaluating Drug Risk Using GAN and SMOTE Based on CFDA’s Spontaneous Reporting Data." Journal of Healthcare Engineering 2021 (August 27, 2021): 1–14. http://dx.doi.org/10.1155/2021/6033860.
Pełny tekst źródłaMadhavan, Suresh, and Prasanna R. Gore. "Influence of Physicians' Attitudes Toward Rx-to-OTC Switches on Their Prescribing Behavior and Overall Judgment of Switch Appropriateness." Journal of Pharmaceutical Marketing & Management 8, no. 1 (1994): 55–84. http://dx.doi.org/10.3109/j058v08n01_05.
Pełny tekst źródłaMadhavan, Suresh. "Influence of Physicians' Attitudes Toward Rx-to-OTC Switches on Their Prescribing Behavior and Overall Judgment of Switch Appropriateness." Journal of Pharmaceutical Marketing & Management 8, no. 1 (1994): 55–84. http://dx.doi.org/10.1300/j058v08n01_05.
Pełny tekst źródłaAndrade, Susan E., Jerry H. Gurwitz, and Leslie S. Fish. "The Effect of an Rx-to-OTC Switch on Medication Prescribing Patterns and Utilization of Physician Services." Medical Care 37, no. 4 (1999): 424–30. http://dx.doi.org/10.1097/00005650-199904000-00012.
Pełny tekst źródłaCreyer, Elizabeth H., Illias Hrsistodoulakis, and Catherine A. Cole. "Changing a drug from Rx to OTC status: the consumer behavior and public policy implications of switch drugs." Journal of Product & Brand Management 10, no. 1 (2001): 52–64. http://dx.doi.org/10.1108/10610420110382821.
Pełny tekst źródłaJaidka, Ridham, Parul Verma, Deepali Thakur, Kiran Bala, Amar Pal Singh, and Ajeet Pal Singh. "Review article on over the counter drugs: Growth, benefits and side effects, RX to OTC switch process, classification, pharmacist role." International Journal of Pharmaceutical Research and Development 7, no. 1 (2025): 305–11. https://doi.org/10.33545/26646862.2025.v7.i1d.124.
Pełny tekst źródłaChang, Dong W., Jonathan Grotts, Chi-hong Tseng, and Eric P. Brass. "Time Trends in Physician Visits for Gastroesophageal Reflux Disease Before and After the Rx-to-OTC Switch of Proton Pump Inhibitors." Journal of Clinical Pharmacology 57, no. 4 (2016): 452–58. http://dx.doi.org/10.1002/jcph.825.
Pełny tekst źródłaSullivan, P., KV Nair, and BV Patel. "PAL1 THE IMPACT OF THE RX-TO-OTC SWITCH OF LORATADINE AND CHANGES IN PRESCRIPTION DRUG BENEFITS ON UTILIZATION AND COST OF THERAPY." Value in Health 8, no. 3 (2005): 338–39. http://dx.doi.org/10.1016/s1098-3015(10)62892-6.
Pełny tekst źródłaSullivan, P., KV Nair, and BV Patel. "PAL1 THE IMPACT OF THE RX-TO-OTC SWITCH OF LORATADINE AND CHANGES IN PRESCRIPTION DRUG BENEFITS ON UTILIZATION AND COST OF THERAPY." Value in Health 8, no. 3 (2005): 339. http://dx.doi.org/10.1016/s1098-3015(10)62893-8.
Pełny tekst źródłaPlich, A., S. M. Karray, S. Flostrand, and M. Toumi. "PRM25 Switch of Prescription Drugs to the Over-the-Counter Status (Rx-to-OTC): The Development of a Flexible and Generic European Budget Impact Model." Value in Health 14, no. 7 (2011): A425. http://dx.doi.org/10.1016/j.jval.2011.08.1056.
Pełny tekst źródłaShiffman, Saul, and Christine T. Sweeney. "Ten years after the Rx-to-OTC switch of nicotine replacement therapy: What have we learned about the benefits and risks of non-prescription availability?" Health Policy 86, no. 1 (2008): 17–26. http://dx.doi.org/10.1016/j.healthpol.2007.08.006.
Pełny tekst źródłaSullivan, Patrick W., and Michael B. Nichol. "The Economic Impact of Payer Policies after the Rx-to-OTC Switch of Second-Generation Antihistamines* *Preliminary results of this analysis were presented at the 9th annual HMO Research Network Conference April 1-2, 2003." Value in Health 7, no. 4 (2004): 402–12. http://dx.doi.org/10.1111/j.1524-4733.2004.74003.x.
Pełny tekst źródłaNewton, Gail, Nicholas G. Popovich, and W. Steven Pray. "Rx-to-OTC Switches: From Prescription to Self-Care." Journal of the American Pharmaceutical Association (1996) 36, no. 8 (1996): 488–95. http://dx.doi.org/10.1016/s1086-5802(16)30103-6.
Pełny tekst źródłaCada, Dennis. "Rx-to-otc Switches for HMG-CoA Reductase Inhibitors." Hospital Pharmacy 35, no. 10 (2000): 1024. http://dx.doi.org/10.1177/001857870003501007.
Pełny tekst źródłaMahecha, Laura A. "Rx-to-OTC switches: trends and factors underlying success." Nature Reviews Drug Discovery 5, no. 5 (2006): 380–86. http://dx.doi.org/10.1038/nrd2028.
Pełny tekst źródłaNarui, Koji, Mayumi Mochizuki, and Kinzo Watanabe. "A Survey of Consumer Views on Rx-to-OTC Switches." Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) 39, no. 12 (2013): 726–32. http://dx.doi.org/10.5649/jjphcs.39.726.
Pełny tekst źródłaKubota, Sachie, Kazuyuki Saito, Shunsuke Ono, and Yasuo Kodama. "Survey of Pharmacists' Views on Rx-to-OTC Switched Drugs." Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) 43, no. 6 (2017): 287–96. http://dx.doi.org/10.5649/jjphcs.43.287.
Pełny tekst źródłaHoy, Mariea Grubbs. "Switch Drugs Vis-à-Vis Rx and OTC: Policy, Marketing, and Research Considerations." Journal of Public Policy & Marketing 13, no. 1 (1994): 85–96. http://dx.doi.org/10.1177/074391569401300107.
Pełny tekst źródłaMadhavan, Suresh, and Prasanna Gore. "A Multidimensional Analysis of Physicians' Perceptions of Rx-to-OTC Switched Drug Products." Journal of Pharmaceutical Marketing & Management 8, no. 3 (1994): 3–28. http://dx.doi.org/10.3109/j058v08n03_02.
Pełny tekst źródłaMadhavan, Suresh. "A Multidimensional Analysis of Physicians' Perceptions of Rx-to-OTC Switched Drug Products." Journal of Pharmaceutical Marketing & Management 8, no. 3 (1994): 3–28. http://dx.doi.org/10.1300/j058v08n03_02.
Pełny tekst źródłaMorris, Louis A., Karen Lechter, Michael Weintraub, and Debra Bowen. "Comprehension Testing for OTC Drug Labels: Goals, Methods, Target Population, and Testing Environment." Journal of Public Policy & Marketing 17, no. 1 (1998): 86–96. http://dx.doi.org/10.1177/074391569801700109.
Pełny tekst źródłaMadhavan, S. "Factors influencing pharmacists' preference for the legal classification of Rx–to–OTC switched drug products." Journal of Clinical Pharmacy and Therapeutics 18, no. 4 (1993): 281–90. http://dx.doi.org/10.1111/j.1365-2710.1993.tb00589.x.
Pełny tekst źródłaCohen, J., A. Millier, S. Karray, and M. Toumi. "Assessing the economic impact of Rx-to-OTC switches: systematic review and guidelines for future development." Journal of Medical Economics 16, no. 6 (2013): 835–44. http://dx.doi.org/10.3111/13696998.2013.793693.
Pełny tekst źródłaNoguchi, Yoshihiro, Aki Yoshida, Ikuto Sugita, et al. "Signal Detection Analysis of Serious Adverse Events Associated with the Digestive Disorder Treatment Agents Rx-To-OTC Switched." Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) 42, no. 7 (2016): 529–35. http://dx.doi.org/10.5649/jjphcs.42.529.
Pełny tekst źródłaKarray, S. M., A. Plich, S. Flostrand, and M. Toumi. "PHP31 The Economic Impact of Switches of Prescription Drugs to the Over-the-Counter Status (Rx-to-OTC): A Systematic Literature Review." Value in Health 14, no. 7 (2011): A338—A339. http://dx.doi.org/10.1016/j.jval.2011.08.582.
Pełny tekst źródłaNoguchi, Yoshihiro, Hiroki Esaki, Shoko Asano, et al. "Analysis of Adverse Events Associated with the Anti-Allergic Agents Rx-to-OTC-Switched Using Data Mining of the Japanese Adverse Drug Event Report (JADER) Database." Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) 41, no. 9 (2015): 667–75. http://dx.doi.org/10.5649/jjphcs.41.667.
Pełny tekst źródłaWaring, Mark, and Amritdeep Gill. "Impact of Switch to Non-Prescription Status on the Safety Profile of Sildenafil and Tadalafil: Assessment of Pharmacovigilance Databases." Indian Journal of Pharmaceutical Sciences, 2024, 01–16. https://doi.org/10.36468/pharmaceutical-sciences.24.12.497.
Pełny tekst źródła